Collaboration Arrangements (Tables)

3 Months Ended

Mar. 31, 2012

Collaboration Arrangements

Schedule of common stock shares purchased in private placements by the affiliate of GSK

	Through March 31, 2012
	Common Stock Shares Purchased	Aggregate Amounts (in thousands)
Purchase dates
February 24, 2011	152,278	$	3,609
May 3, 2011	261,299	$	6,689
August 2, 2011	102,466	$	2,020
November 1, 2011	58,411	$	1,298
February 14, 2012	88,468	$	1,603

Schedule of upfront license fees and milestone payments received from GSK under the LABA collaboration and strategic alliance agreements

	Through March 31, 2012
(in thousands)	Upfront Fees		Milestone Payments		Total
GSK Collaborations
LABA/RELOVAIR™ collaboration(1)	$	10,000	$	50,000	$	60,000
Strategic alliance agreement	20,000		—		20,000
Strategic alliance—LAMA license(2)	5,000		3,000		8,000
Strategic alliance—MABA program license	6,000		16,000		22,000
Total	$	41,000	$	69,000	$	110,000

(1)The Company does not currently expect to be eligible for any additional milestones under this collaboration.

(2)In August 2004, GSK exercised its right to license the Company’s LAMA program pursuant to the terms of the strategic alliance. In 2009, GSK returned the program to the Company.

Schedule of revenue recognized from GSK under the LABA collaboration and strategic alliance agreements

	Three Months Ended March 31,
(in thousands)	2012		2011
GSK Collaborations
LABA/RELOVAIR™ collaboration	$	907	$	1,270
Strategic alliance agreement	—		684
Strategic alliance—MABA program license	523		502
Total	$	1,430	$	2,456

Schedule of revenue recognized under the Astellas collaboration agreement

	Three Months Ended March 31,
(in thousands)	2012			2011
Recognition of deferred revenue	$	125,819		$	3,244
Royalties from net sales of VIBATIV®	—			631
Astellas-labeled product sales allowance	(150		)	—
Total net revenue	$	125,669		$	3,875